| Name | Title | Contact Details |
|---|
Med-X Global is an LLC formed in the State of New Jersey. We operate as international revenue cycle consultants, third-party medical claims administrators and payment collectors adjudicating emergency medical claims for highly accredited foreign hospitals. Med-X also serves the ancillary emergency provider community in the foreign marketplace to include air and ground ambulance entities as well as premier urgent care centers and physician administered emergency sites. The majority of Med-X`s hospital clients operate clinically sophisticated facilities accredited by the General Heath Council (CSG) while still others are accredited by the Joint Commission International (JCI) reflecting a standard of care that typically meets or even exceeds the U.S. benchmark for quality providers.
Zanthion protects the elderly from harm, automatically notifies near responders to avoid catastrophic damage, offers solace until help arrives, predicts future needs through artificial intelligence, and connects seniors to the world and their community. Zanthion is a pioneer in changing our social environment with future vision and use case (solution based) systems that improve the world based on open source, transparent, crowdsourced economic mechanisms that accurately assess what happened, inform the correct resources that the event has occurred, provide resources to the problem efficiently, and keep track of the efficiency of fixing the non-conformity. Our platform is generic and it is open. We embrace a responsible future.
Angela Hospice is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SleepImage Ring The SleepImage Rings stream data to the SleepImage Mobile App for upload, offering the highest level of comfort and convenience. SleepImage Mobile App The SleepImage Mobile App collects sleep data and automatically uploads it in the mo...
Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.